{"id":29837,"date":"2026-10-18T14:44:00","date_gmt":"2026-10-18T21:44:00","guid":{"rendered":"https:\/\/getheally.com\/patients\/news\/how-to-switch-from-compounded-semaglutide-to-compounded-tirzepatide-copy"},"modified":"2026-10-20T08:12:44","modified_gmt":"2026-10-20T15:12:44","slug":"tirzepatide-vs-semaglutide-dosage-for-weight-loss","status":"publish","type":"post","link":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","title":{"rendered":"Tirzepatide vs semaglutide: dosage, weight loss results and which is right for you (2026)"},"content":{"rendered":"<p><i><span style=\"font-weight: 400;\">Editorial note: Heally providers prescribe both semaglutide and tirzepatide, so we have a stake in this topic. We base this comparison on FDA labels and published clinical trials, linked in the sources below. The choice of medication is made by you and your provider, based on your health history.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400;\">Tirzepatide and semaglutide are the two leading GLP-1 medications for weight loss and type 2 diabetes. <\/span><a href=\"https:\/\/getheally.com\/patients\/semaglutide\"><span style=\"font-weight: 400;\">Semaglutide<\/span><\/a><span style=\"font-weight: 400;\"> is sold as Ozempic, Wegovy and Rybelsus, and the Wegovy pill. <\/span><a href=\"https:\/\/getheally.com\/patients\/weight-loss-info\/what-is-tirzepatide\"><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/a><span style=\"font-weight: 400;\"> is sold as Mounjaro and Zepbound. They are often discussed together and prescribed for similar conditions. Still, they are different drugs, with different mechanisms, dosing schedules, results, approvals and ideal candidates.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This guide compares tirzepatide and semaglutide dosage, weight loss, side effects and cost, using the latest trial data and FDA labels as of October 2026. You can use it to prepare for a conversation with your provider.<\/span><\/p>\n<h2 id=\"key-takeaways\"><span style=\"font-weight: 400;\">Key takeaways<\/span><\/h2>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tirzepatide is a once-weekly injection. Semaglutide comes as a once-weekly injection (Ozempic, Wegovy) or a daily pill (Rybelsus, Wegovy pill)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tirzepatide is a dual GLP-1 and GIP receptor agonist. Semaglutide is a GLP-1 receptor agonist only. This is the core mechanistic difference<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">In the SURMOUNT-5 head-to-head trial (NEJM 2025), tirzepatide led to 20.2% average weight loss vs 13.7% with semaglutide over 72 weeks<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tirzepatide dosing starts at 2.5 mg and goes up to 15 mg weekly. Wegovy starts at 0.25 mg and goes up to 2.4 mg, or 7.2 mg with Wegovy HD<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Side effect profiles are broadly similar, and both carry the same FDA boxed warning for thyroid C-cell tumors<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Both now have proven cardiovascular data. Wegovy&#8217;s comes from the SELECT trial, and Mounjaro&#8217;s from SURPASS-CVOT (FDA approval in August 2026)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The right choice depends on your goals, health history, insurance and individual response, not just average results<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Talk to a <\/span><a href=\"https:\/\/getheally.com\/patients\/weight-loss-prescription\"><span style=\"font-weight: 400;\">Heally licensed provider<\/span><\/a><span style=\"font-weight: 400;\"> about which medication fits you<\/span><\/li>\n<\/ul>\n<h2 id=\"the-core-difference-between-semaglutide-and-tirzepatide-how-each-drug-works\"><span style=\"font-weight: 400;\">The core difference between semaglutide and tirzepatide: how each drug works<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The most important difference between tirzepatide and semaglutide is their mechanism of action, meaning which hormone receptors they activate.<\/span><\/p>\n<h3 id=\"semaglutide\"><span style=\"font-weight: 400;\">Semaglutide<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a gut hormone released after eating. It signals the brain to reduce appetite and slows stomach emptying, so you feel full longer. It also boosts insulin release and lowers glucagon, which would otherwise raise blood sugar. Semaglutide mimics this hormone but lasts much longer, so once-weekly dosing works.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Considering semaglutide? Compare <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/wegovy\"><i><span style=\"font-weight: 400;\">Wegovy injections<\/span><\/i><\/a><i><span style=\"font-weight: 400;\"> and <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/wegovy-pills\"><i><span style=\"font-weight: 400;\">Wegovy pills<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">. A Heally provider will review your health history and prescribe only if it&#8217;s right for you.<\/span><\/i><\/p>\n<h3 id=\"tirzepatide\"><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, sometimes called a &#8220;twincretin.&#8221; GIP is a second gut hormone involved in insulin release, fat storage and energy use. By activating both receptors, tirzepatide has broader metabolic effects than GLP-1 activation alone. Research suggests GIP action in fat tissue may also help explain tirzepatide&#8217;s larger weight loss in trials, though scientists are still studying exactly how.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Considering tirzepatide? Learn about <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/zepbound\"><i><span style=\"font-weight: 400;\">Zepbound<\/span><\/i><\/a><i><span style=\"font-weight: 400;\"> or start with Heally&#8217;s <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/tirzepatide\"><i><span style=\"font-weight: 400;\">tirzepatide program<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">. Your provider will check whether it&#8217;s a safe fit before prescribing.<\/span><\/i><\/p>\n<p><b>Mechanism edge: tirzepatide.<\/b><span style=\"font-weight: 400;\"> Tirzepatide&#8217;s dual GLP-1 and GIP action creates broader metabolic effects. Still, both mechanisms are clinically proven. Semaglutide&#8217;s GLP-1-only approach produces substantial, well-documented weight loss and blood sugar control on its own. For a plain-language explainer of the two drugs, see <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide\"><span style=\"font-weight: 400;\">tirzepatide vs semaglutide: what&#8217;s the difference<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2 id=\"fda-approvals-what-each-drug-is-officially-indicated-for\"><span style=\"font-weight: 400;\">FDA approvals: what each drug is officially indicated for<\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th><b>Indication<\/b><\/th>\n<th><b>Semaglutide<\/b><\/th>\n<th><b>Tirzepatide<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">Type 2 diabetes<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Ozempic (injection), Rybelsus (pill)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Mounjaro<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Chronic weight management<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy injection, Wegovy HD and Wegovy pill<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cardiovascular risk reduction<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy (adults with obesity and heart disease), Ozempic (type 2 diabetes)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Mounjaro (adults with type 2 diabetes at high cardiovascular risk, approved 2026)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Obstructive sleep apnea (OSA)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not approved<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound (approved 2024)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">MASH (liver disease with fibrosis)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy 2.4 mg (accelerated approval, 2025)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not approved<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Adolescents with obesity (12 to 17)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not approved under 18<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Children with type 2 diabetes (10 to 17)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Not approved for Ozempic<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Mounjaro (ages 10 and older)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Oral form<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Rybelsus (type 2 diabetes), Wegovy pill (weight loss)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Injection only<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">Sources: FDA prescribing information for Wegovy, Mounjaro and Zepbound; <\/span><\/i><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s023lbl.pdf\"><i><span style=\"font-weight: 400;\">FDA Wegovy label 2025<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">; <\/span><\/i><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/215866s009lbl.pdf\"><i><span style=\"font-weight: 400;\">FDA Mounjaro label 2026<\/span><\/i><\/a><\/p>\n<p><b>Approval breadth edge: semaglutide.<\/b><span style=\"font-weight: 400;\"> Semaglutide holds more FDA indications, including weight-related heart protection, adolescent use, liver disease (MASH) and two oral forms. Tirzepatide is catching up. It added sleep apnea in 2024 and cardiovascular risk reduction for type 2 diabetes in 2026.<\/span><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-efficacy-in-weight-loss-comparison\"><span style=\"font-weight: 400;\">Semaglutide and tirzepatide efficacy in weight loss comparison<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">This is where the two drugs diverge most clearly, and where the strongest clinical evidence now exists.<\/span><\/p>\n<table>\n<thead>\n<tr>\n<th><b>Drug<\/b><\/th>\n<th><b>Trial<\/b><\/th>\n<th><b>Duration<\/b><\/th>\n<th><b>Dose<\/b><\/th>\n<th><b>Average weight loss<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURMOUNT-5 (head-to-head)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Max tolerated, 10 or 15 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20.2%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Semaglutide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURMOUNT-5 (head-to-head)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Max tolerated, 1.7 or 2.4 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">13.7%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Tirzepatide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURMOUNT-1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20.9%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Semaglutide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">STEP 1<\/span><\/td>\n<td><span style=\"font-weight: 400;\">68 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.4 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">14.9%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Semaglutide<\/span><\/td>\n<td><span style=\"font-weight: 400;\">STEP UP<\/span><\/td>\n<td><span style=\"font-weight: 400;\">72 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">7.2 mg (Wegovy HD)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About 19% to 21%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">SURMOUNT-1 and STEP 1 were separate placebo-controlled trials, so compare them with caution. Only SURMOUNT-5 tested the two drugs directly against each other.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400;\">The SURMOUNT-5 trial was published in the <\/span><i><span style=\"font-weight: 400;\">New England Journal of Medicine<\/span><\/i><span style=\"font-weight: 400;\"> in May 2025. It was the first randomized, head-to-head comparison of the two medications in adults with obesity but without type 2 diabetes. It enrolled 751 adults and ran for 72 weeks, with each drug at its maximum tolerated dose. Tirzepatide led to 20.2% average weight loss, compared with 13.7% for semaglutide. That&#8217;s a statistically significant 6.5 percentage point difference. People on tirzepatide were also more likely to reach 10%, 15%, 20% and 25% weight loss.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A 2025 meta-analysis of many studies confirmed tirzepatide&#8217;s advantage. It found about 4 percentage points more weight loss with tirzepatide on average, and the gap grew with higher doses and longer treatment. Real-world data point the same way. In a 2024 <\/span><i><span style=\"font-weight: 400;\">JAMA Internal Medicine<\/span><\/i><span style=\"font-weight: 400;\"> study of more than 18,000 US adults, tirzepatide users lost about 15.3% of their body weight at 12 months, compared with 8.3% for semaglutide users.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">One 2026 update narrows the gap. Wegovy HD (semaglutide 7.2 mg) was approved in March 2026 for people who have tolerated 2.4 mg for at least 4 weeks and need more weight loss. In the STEP UP trial, its results came close to tirzepatide&#8217;s.<\/span><\/p>\n<p><b>Weight loss edge: tirzepatide.<\/b><span style=\"font-weight: 400;\"> Tirzepatide produces greater average weight loss than standard-dose semaglutide in head-to-head trials and real-world data. That said, semaglutide still produces meaningful, life-improving weight loss for most people who take it. For month-by-month expectations, see <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-much-weight-can-you-lose-on-mounjaro-in-a-month\"><span style=\"font-weight: 400;\">how much weight you can lose on Mounjaro in a month<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-efficacy-in-blood-sugar-control-for-type-2-diabetes\"><span style=\"font-weight: 400;\">Semaglutide and tirzepatide efficacy in blood sugar control for type 2 diabetes<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Both medications significantly lower HbA1c, the key long-term blood sugar marker. Tirzepatide again shows stronger results in head-to-head comparisons.<\/span><\/p>\n<table>\n<thead>\n<tr>\n<th><b>Metric<\/b><\/th>\n<th><b>Tirzepatide<\/b><\/th>\n<th><b>Semaglutide<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">HbA1c reduction (top doses, trials)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-2.0% to -2.4%<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.6% to -1.9%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">HbA1c reduction (real-world, 12 months)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.3% (GLP-1 naive patients)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-0.9% (GLP-1 naive patients)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Weight lost (real-world, type 2 diabetes, 12 months)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-10.2 kg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-6.1 kg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">SURPASS-2 vs semaglutide 1 mg (HbA1c)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-2.0% to -2.3% (all tirzepatide doses)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">-1.86%<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cardiovascular outcomes trial<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SURPASS-CVOT: 8% fewer major events vs dulaglutide (not statistically superior)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">SELECT: 20% fewer major events vs placebo<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">Sources: <\/span><\/i><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12579026\/\"><i><span style=\"font-weight: 400;\">Real-world HbA1c study, PMC 2025<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">; <\/span><\/i><a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2107519\"><i><span style=\"font-weight: 400;\">SURPASS-2, NEJM 2021<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">; <\/span><\/i><a href=\"https:\/\/www.pharmacytimes.com\/view\/fda-approves-tirzepatide-to-cut-cv-risk-in-type-2-diabetes\"><i><span style=\"font-weight: 400;\">SURPASS-CVOT approval, Pharmacy Times 2026<\/span><\/i><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Heart protection is an important difference to understand. The SELECT trial (2023) showed that Wegovy lowered the risk of major adverse cardiovascular events (MACE), such as heart attack, stroke and cardiovascular death, by 20% compared with placebo. It included people with obesity and established heart disease, without diabetes.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Tirzepatide&#8217;s SURPASS-CVOT trial reported in 2025. It compared tirzepatide with dulaglutide, another GLP-1 drug with proven heart benefits, in 13,299 adults with type 2 diabetes and heart disease. Tirzepatide had 8% fewer major events. That met the goal of being at least as good as dulaglutide, but was not statistically better. In August 2026, the FDA approved Mounjaro to lower cardiovascular risk in adults with type 2 diabetes at high risk.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For people with heart disease and obesity but no diabetes, semaglutide still has the more direct evidence. Talk this through with your provider if you have a history of heart attack or stroke.<\/span><\/p>\n<p><b>2026 update.<\/b><span style=\"font-weight: 400;\"> In August 2025, the FDA granted accelerated approval to Wegovy 2.4 mg for MASH (formerly NASH) with moderate to advanced liver fibrosis. In December 2025, the Wegovy pill became the first oral GLP-1 approved for weight loss. In March 2026, Wegovy HD (7.2 mg) was approved for additional weight loss. For tirzepatide, Zepbound was approved for obstructive sleep apnea in adults with obesity in December 2024. It was the first medication approved for OSA. Mounjaro added a cardiovascular indication in August 2026.<\/span><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-dosing-comparison\"><span style=\"font-weight: 400;\">Semaglutide and tirzepatide dosing comparison<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Dosing is one of the most practical differences between tirzepatide and semaglutide. The numbers aren&#8217;t comparable milligram for milligram. A 2.4 mg dose of semaglutide is not &#8220;weaker&#8221; than 15 mg of tirzepatide just because the number is smaller, since they are different molecules.<\/span><\/p>\n<table>\n<thead>\n<tr>\n<th><b>Dosing feature<\/b><\/th>\n<th><b>Semaglutide<\/b><\/th>\n<th><b>Tirzepatide<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">Starting dose<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.25 mg weekly (Ozempic, Wegovy); 1.5 mg daily (Wegovy pill); 3 mg daily (Rybelsus)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.5 mg weekly<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Titration interval<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Every 4 weeks<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Every 4 weeks, in 2.5 mg steps<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Maintenance doses<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Ozempic 0.5, 1 or 2 mg; Wegovy 1.7 or 2.4 mg; Wegovy pill 25 mg daily<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5, 10 or 15 mg weekly (Zepbound); up to 15 mg (Mounjaro)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Maximum dose<\/span><\/td>\n<td><span style=\"font-weight: 400;\">7.2 mg weekly (Wegovy HD); 2 mg weekly (Ozempic)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15 mg weekly<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Time to reach top standard dose<\/span><\/td>\n<td><span style=\"font-weight: 400;\">16 weeks to 2.4 mg (Wegovy)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">20 weeks to 15 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">How it&#8217;s taken<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Injection or daily pill<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Injection only<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Devices<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy single-dose pen; Ozempic multi-dose pen; tablets<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound single-dose pen, KwikPen and vials; Mounjaro single-dose pen<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Half-life<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About 7 days<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About 5 days<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Missed dose window<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy: take within 5 days; Ozempic: within 5 days<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Within 4 days<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3 id=\"tirzepatide-dosing-schedule\"><span style=\"font-weight: 400;\">Tirzepatide dosing schedule<\/span><\/h3>\n<table>\n<thead>\n<tr>\n<th><b>Weeks<\/b><\/th>\n<th><b>Tirzepatide dose<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">1 to 4<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.5 mg (starter dose)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">5 to 8<\/span><\/td>\n<td><span style=\"font-weight: 400;\">5 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">9 to 12<\/span><\/td>\n<td><span style=\"font-weight: 400;\">7.5 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">13 to 16<\/span><\/td>\n<td><span style=\"font-weight: 400;\">10 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">17 to 20<\/span><\/td>\n<td><span style=\"font-weight: 400;\">12.5 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">21 onward<\/span><\/td>\n<td><span style=\"font-weight: 400;\">15 mg (if needed)<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3 id=\"wegovy-semaglutide-dosing-schedule\"><span style=\"font-weight: 400;\">Wegovy (semaglutide) dosing schedule<\/span><\/h3>\n<table>\n<thead>\n<tr>\n<th><b>Weeks<\/b><\/th>\n<th><b>Wegovy dose<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">1 to 4<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.25 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">5 to 8<\/span><\/td>\n<td><span style=\"font-weight: 400;\">0.5 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">9 to 12<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">13 to 16<\/span><\/td>\n<td><span style=\"font-weight: 400;\">1.7 mg<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">17 onward<\/span><\/td>\n<td><span style=\"font-weight: 400;\">2.4 mg (maintenance), or 1.7 mg if 2.4 mg isn&#8217;t tolerated<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">After at least 4 weeks on 2.4 mg<\/span><\/td>\n<td><span style=\"font-weight: 400;\">7.2 mg (Wegovy HD), if your provider recommends more weight loss<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">You don&#8217;t have to reach the top dose on either drug. Many people stay on a lower dose that works well for them. Your provider may also keep you at a dose longer if side effects are hard to manage. For timing rules, see <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-long-to-stay-on-each-glp-1-dose-level-before-increasing\"><span style=\"font-weight: 400;\">how long to stay on each GLP-1 dose before increasing<\/span><\/a><span style=\"font-weight: 400;\">, our full <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-dosing-guide\"><span style=\"font-weight: 400;\">tirzepatide dosing guide<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/what-should-you-know-about-the-highest-dose-of-mounjaro\"><span style=\"font-weight: 400;\">what to know about the highest dose of Mounjaro<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h3 id=\"is-there-an-equivalent-dose-between-tirzepatide-and-semaglutide\"><span style=\"font-weight: 400;\">Is there an equivalent dose between tirzepatide and semaglutide?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">There is no official conversion. When people switch, providers usually look at the current dose, how well it&#8217;s working and side effects. For example, someone on Wegovy 2.4 mg who switches to tirzepatide often starts at 2.5 mg or 5 mg, depending on the provider&#8217;s judgment. Never switch on your own. See <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-switch-from-zepbound-to-wegovy\"><span style=\"font-weight: 400;\">how to switch from Zepbound to Wegovy<\/span><\/a><span style=\"font-weight: 400;\"> for what the process looks like.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Comparing pills and shots? Read our <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/news\/wegovy-pills-vs-injection-a-complete-comparison-guide-for-2026\"><i><span style=\"font-weight: 400;\">Wegovy pills vs injection guide<\/span><\/i><\/a><i><span style=\"font-weight: 400;\"> \u00b7 Learn about <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/foundayo\"><i><span style=\"font-weight: 400;\">Foundayo<\/span><\/i><\/a><i><span style=\"font-weight: 400;\">, another daily GLP-1 pill \u00b7 Check your baseline with a <\/span><\/i><a href=\"https:\/\/getheally.com\/patients\/test-for-weight-loss\"><i><span style=\"font-weight: 400;\">weight loss lab panel<\/span><\/i><\/a><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-side-effects-how-do-they-compare\"><span style=\"font-weight: 400;\">Semaglutide and tirzepatide side effects: how do they compare?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Because both drugs activate the GLP-1 pathway, their side effects are very similar. The differences are of degree, not kind.<\/span><\/p>\n<p><b>Common side effects shared by both medications:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Nausea, the most common, which usually peaks during dose increases and then eases<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Vomiting<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Diarrhea or constipation<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Decreased appetite and early fullness<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Bloating or stomach discomfort<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Injection site reactions (injections only)<\/span><\/li>\n<\/ul>\n<p><b>Key safety warnings that apply to both drugs:<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>FDA boxed warning:<\/b><span style=\"font-weight: 400;\"> possible risk of thyroid C-cell tumors, based on animal studies. Neither drug should be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Pancreatitis:<\/b><span style=\"font-weight: 400;\"> both carry a warning. Stop the medication and get care if it&#8217;s suspected<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Gallbladder disease:<\/b><span style=\"font-weight: 400;\"> both raise the risk of gallstones and gallbladder inflammation, especially with rapid weight loss<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Low blood sugar:<\/b><span style=\"font-weight: 400;\"> mainly in people with type 2 diabetes who also take insulin or a sulfonylurea<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Kidney problems:<\/b><span style=\"font-weight: 400;\"> severe vomiting or diarrhea can cause dehydration and acute kidney injury<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Birth control pills (tirzepatide only):<\/b><span style=\"font-weight: 400;\"> tirzepatide can make birth control pills less effective. Lilly advises a backup method for 4 weeks after starting and after each dose increase<\/span><\/li>\n<\/ul>\n<h3 id=\"where-do-they-differ-in-side-effects\"><span style=\"font-weight: 400;\">Where do they differ in side effects?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In most comparisons, overall rates of digestive side effects are similar. Some meta-analyses found slightly higher rates of serious adverse events at higher tirzepatide doses (10 to 15 mg) than with semaglutide. However, results vary between studies, and the absolute differences are small. Appetite suppression can also feel stronger on tirzepatide. Some people welcome that, while others find it uncomfortable.<\/span><\/p>\n<p><b>Side effect tolerability edge: semaglutide (slight).<\/b><span style=\"font-weight: 400;\"> Both drugs have similar side effect profiles overall. Semaglutide has a slightly better serious adverse event rate in some comparative data. It also has a longer real-world safety track record, with Wegovy approved for weight loss since 2021 and Ozempic since 2017. For a deeper look, see <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/what-medication-has-fewer-side-effects-semaglutide-or-tirzepatide-2\"><span style=\"font-weight: 400;\">which has fewer side effects, semaglutide or tirzepatide<\/span><\/a><span style=\"font-weight: 400;\"> and our guide to <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-side-effects\"><span style=\"font-weight: 400;\">tirzepatide side effects<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2 id=\"semaglutide-and-tirzepatide-difference-in-cost-and-insurance-in-2026\"><span style=\"font-weight: 400;\">Semaglutide and tirzepatide difference in cost and insurance in 2026<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Cost is often the deciding factor. Brand-name versions of both medications are expensive at list price, but self-pay options have changed the picture in 2026.<\/span><\/p>\n<table>\n<thead>\n<tr>\n<th><b>Cost factor<\/b><\/th>\n<th><b>Semaglutide<\/b><\/th>\n<th><b>Tirzepatide<\/b><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><span style=\"font-weight: 400;\">Brand-name list price per month<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About $1,000 to $1,350 (Ozempic, Wegovy)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About $1,050 to $1,100 (Mounjaro, Zepbound)<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Manufacturer self-pay price<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy pens <\/span><span style=\"font-weight: 400;\">349\/month(<\/span><span style=\"font-weight: 400;\">199 for the first 2 fills through 12\/31\/2026); Wegovy HD $399; Wegovy pill $149 to $299<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound through LillyDirect from $299\/month<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Savings card with commercial insurance<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Wegovy savings offer (as low as $25, with a monthly cap)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Zepbound savings card<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Medicare<\/span><\/td>\n<td><span style=\"font-weight: 400;\">GLP-1 Bridge program: $50\/month for Wegovy (7\/1\/2026 to 12\/31\/2027)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">GLP-1 Bridge program: $50\/month for Zepbound<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Insurance coverage for obesity<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Varies by plan; Wegovy has a longer formulary history<\/span><\/td>\n<td><span style=\"font-weight: 400;\">Varies by plan; Zepbound coverage is growing<\/span><\/td>\n<\/tr>\n<tr>\n<td><span style=\"font-weight: 400;\">Cost per 1% of body weight lost (list price)<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About $1,845<\/span><\/td>\n<td><span style=\"font-weight: 400;\">About $985<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><i><span style=\"font-weight: 400;\">Prices as of October 2026 and subject to change. Confirm current pricing with your pharmacy, insurer or the manufacturer. Cost-per-outcome figures are based on list prices. Source: <\/span><\/i><a href=\"https:\/\/www.drugs.com\/medical-answers\/tirzepatide-semaglutide-how-compare-3576410\/\"><i><span style=\"font-weight: 400;\">Drugs.com comparison<\/span><\/i><\/a><\/p>\n<p><i><span style=\"font-weight: 400;\">At list prices, tirzepatide&#8217;s greater weight loss makes it nearly 2 times more cost-efficient per unit of outcome. Source: Drugs.com.<\/span><\/i><\/p>\n<p><span style=\"font-weight: 400;\">Measured as cost per percentage point of body weight lost, tirzepatide is more cost-efficient at brand-name prices. Its list price is similar, but it produces more weight loss per dollar. Your actual cost depends on your insurance, savings programs and which version you use.<\/span><\/p>\n<p><b>A note on compounded GLP-1s.<\/b><span style=\"font-weight: 400;\"> The FDA removed tirzepatide from its drug shortage list in December 2024 and semaglutide in February 2025. Since then, pharmacies can no longer mass-produce copies of these drugs. Compounded versions are not FDA approved, and the FDA has received reports of dosing errors and hospitalizations linked to them. If you&#8217;re considering a compounded option, ask your provider why it&#8217;s medically necessary for you and which pharmacy makes it.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">For more on pricing, see <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/what-youll-pay-for-wegovy-with-no-insurance\"><span style=\"font-weight: 400;\">what you&#8217;ll pay for Wegovy with no insurance<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/getheally.com\/patients\/news\/how-to-use-a-discount-for-zepbound-from-eli-lilly\"><span style=\"font-weight: 400;\">how to use the Zepbound savings card<\/span><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<h2 id=\"who-should-choose-tirzepatide\"><span style=\"font-weight: 400;\">Who should choose tirzepatide?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Tirzepatide may be a better fit for:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People whose main goal is maximum weight loss, and who want the drug with the strongest head-to-head data<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People who have plateaued on semaglutide and need a more potent option<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Adults with obesity and obstructive sleep apnea, since Zepbound is approved for OSA<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People with type 2 diabetes who need a stronger HbA1c reduction<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People with type 2 diabetes and high cardiovascular risk, now that Mounjaro has a cardiovascular indication<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People whose insurance or self-pay price makes tirzepatide comparable to or cheaper than semaglutide<\/span><\/li>\n<\/ul>\n<h2 id=\"who-should-choose-semaglutide\"><span style=\"font-weight: 400;\">Who should choose semaglutide?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Semaglutide may be a better fit for:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People with obesity and established heart disease but no diabetes, who benefit from the SELECT trial&#8217;s proven reduction in heart attack and stroke<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Teens aged 12 to 17 with obesity, since Wegovy is approved for this age group and tirzepatide is not<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People who prefer a pill, such as the Wegovy pill for weight loss or <\/span><a href=\"https:\/\/getheally.com\/patients\/rybelsus\"><span style=\"font-weight: 400;\">Rybelsus<\/span><\/a><span style=\"font-weight: 400;\"> for type 2 diabetes<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People with MASH and liver fibrosis, since Wegovy 2.4 mg is approved for this condition<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">People for whom semaglutide is more affordable or better covered by insurance<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">First-time GLP-1 users who want the medication with the longest real-world safety track record<\/span><\/li>\n<\/ul>\n<h2 id=\"the-bottom-line\"><span style=\"font-weight: 400;\">The bottom line<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Tirzepatide and semaglutide both lead to significant weight loss and better blood sugar control. In the SURMOUNT-5 head-to-head trial, tirzepatide led to more weight loss: 20.2% vs 13.7% over 72 weeks. Tirzepatide is dosed from 2.5 mg to 15 mg weekly, while Wegovy goes from 0.25 mg to 2.4 mg, or 7.2 mg with Wegovy HD. Semaglutide offers more FDA approvals, pill options and the most direct heart-protection evidence for people without diabetes. Side effects are similar for both. Cost depends heavily on your insurance and self-pay options. The best choice depends on your goals, health history and budget, and it&#8217;s a decision to make with a licensed provider.<\/span><\/p>\n<h2 id=\"frequently-asked-questions\"><span style=\"font-weight: 400;\">Frequently asked questions<\/span><\/h2>\n<h3 id=\"is-tirzepatide-stronger-than-semaglutide\"><span style=\"font-weight: 400;\">Is tirzepatide stronger than semaglutide?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In terms of average weight loss and blood sugar reduction, yes. In the SURMOUNT-5 head-to-head trial, tirzepatide led to about 20% weight loss vs about 14% with semaglutide over 72 weeks. However, &#8220;stronger&#8221; doesn&#8217;t mean right for everyone. Individual responses vary, and semaglutide produces meaningful results for most people who take it.<\/span><\/p>\n<h3 id=\"what-is-the-tirzepatide-dose-equivalent-to-semaglutide\"><span style=\"font-weight: 400;\">What is the tirzepatide dose equivalent to semaglutide?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">There is no official dose conversion. The two drugs are different molecules, so milligrams can&#8217;t be compared directly. When switching, providers choose a starting dose based on your current dose, results and side effects.<\/span><\/p>\n<h3 id=\"can-i-take-tirzepatide-and-semaglutide-together\"><span style=\"font-weight: 400;\">Can I take tirzepatide and semaglutide together?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">No. These medications should not be taken at the same time. Both act on GLP-1 receptors, so combining them raises the risk of severe digestive side effects and low blood sugar, with no proven extra benefit. If you switch, your provider will usually have you start the new medication when your next dose of the old one would be due.<\/span><\/p>\n<h3 id=\"which-is-better-for-weight-loss-ozempic-or-mounjaro\"><span style=\"font-weight: 400;\">Which is better for weight loss: Ozempic or Mounjaro?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Mounjaro (tirzepatide) produces more weight loss on average than Ozempic (semaglutide) in clinical trials. However, both are approved for type 2 diabetes, not weight loss. Wegovy and Zepbound are the weight loss versions, so for obesity the relevant comparison is Zepbound vs Wegovy. See our pages on <\/span><a href=\"https:\/\/getheally.com\/patients\/ozempic\"><span style=\"font-weight: 400;\">Ozempic<\/span><\/a><span style=\"font-weight: 400;\"> and <\/span><a href=\"https:\/\/getheally.com\/patients\/mounjaro\"><span style=\"font-weight: 400;\">Mounjaro<\/span><\/a><span style=\"font-weight: 400;\"> for details.<\/span><\/p>\n<h3 id=\"which-drug-has-fewer-side-effects\"><span style=\"font-weight: 400;\">Which drug has fewer side effects?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Both have similar side effect profiles, mostly digestive symptoms such as nausea, vomiting, diarrhea and constipation. Some data show slightly higher rates of serious adverse events with high-dose tirzepatide (10 to 15 mg). If you had intolerable side effects on one medication, switching to the other under medical supervision may help.<\/span><\/p>\n<h3 id=\"does-semaglutide-have-better-cardiovascular-benefits-than-tirzepatide\"><span style=\"font-weight: 400;\">Does semaglutide have better cardiovascular benefits than tirzepatide?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">For people with obesity and heart disease but no diabetes, semaglutide has the stronger evidence. The SELECT trial showed a 20% reduction in heart attack, stroke and cardiovascular death. For people with type 2 diabetes, tirzepatide&#8217;s SURPASS-CVOT trial showed results at least as good as dulaglutide, and Mounjaro was approved to reduce cardiovascular risk in August 2026.<\/span><\/p>\n<h3 id=\"which-is-more-cost-effective\"><span style=\"font-weight: 400;\">Which is more cost-effective?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">At list prices, tirzepatide is more cost-efficient per percentage point of weight lost: about $985 vs $1,845 per 1%. In 2026, manufacturer self-pay prices start at $299 a month for Zepbound and $349 a month for Wegovy pens. Your actual cost depends on your insurance and savings programs.<\/span><\/p>\n<h3 id=\"is-there-a-generic-version-of-tirzepatide-or-semaglutide\"><span style=\"font-weight: 400;\">Is there a generic version of tirzepatide or semaglutide?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">No. As of October 2026, there are no FDA-approved generics of tirzepatide or semaglutide in the US. Both are still under patent protection. Generic liraglutide, an older daily GLP-1, has been available since 2024. Compounded versions are not FDA approved, and mass compounding ended after the drug shortages were resolved in 2024 and 2025.<\/span><\/p>\n<h2 id=\"sources\"><span style=\"font-weight: 400;\">Sources<\/span><\/h2>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Aronne LJ, et al. &#8220;Tirzepatide as Compared with Semaglutide for the Treatment of Obesity&#8221; (SURMOUNT-5). <\/span><i><span style=\"font-weight: 400;\">New England Journal of Medicine<\/span><\/i><span style=\"font-weight: 400;\">, 2025. <\/span><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2416394\"><span style=\"font-weight: 400;\">nejm.org<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Rodriguez PJ, et al. &#8220;Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.&#8221; <\/span><i><span style=\"font-weight: 400;\">JAMA Internal Medicine<\/span><\/i><span style=\"font-weight: 400;\">, 2024. <\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2821080\"><span style=\"font-weight: 400;\">jamanetwork.com<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Meta-analysis: comparative efficacy of tirzepatide vs semaglutide. PMC, 2025. <\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12151102\/\"><span style=\"font-weight: 400;\">pmc.ncbi.nlm.nih.gov<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Real-world HbA1c and weight outcomes: tirzepatide vs semaglutide in type 2 diabetes. PMC, 2025. <\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12579026\/\"><span style=\"font-weight: 400;\">pmc.ncbi.nlm.nih.gov<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fr\u00edas JP, et al. &#8220;Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes&#8221; (SURPASS-2). <\/span><i><span style=\"font-weight: 400;\">New England Journal of Medicine<\/span><\/i><span style=\"font-weight: 400;\">, 2021. <\/span><a href=\"https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2107519\"><span style=\"font-weight: 400;\">nejm.org<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pharmacy Times. &#8220;FDA approves tirzepatide to cut CV risk in type 2 diabetes,&#8221; August 2026. <\/span><a href=\"https:\/\/www.pharmacytimes.com\/view\/fda-approves-tirzepatide-to-cut-cv-risk-in-type-2-diabetes\"><span style=\"font-weight: 400;\">pharmacytimes.com<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">HCPLive. &#8220;FDA approves higher-dose semaglutide (Wegovy HD) injection 7.2 mg for obesity,&#8221; March 2026. <\/span><a href=\"https:\/\/hcplive.com\/view\/fda-approves-higher-dose-semaglutide-wegovy-hd-injection-7-2-mg-for-obesity\"><span style=\"font-weight: 400;\">hcplive.com<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">HCPLive. &#8220;FDA approves semaglutide (Wegovy) injection 2.4 mg for noncirrhotic MASH,&#8221; August 2025. <\/span><a href=\"https:\/\/www.hcplive.com\/view\/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash\"><span style=\"font-weight: 400;\">hcplive.com<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">US Food and Drug Administration. &#8220;FDA&#8217;s concerns with unapproved GLP-1 drugs used for weight loss.&#8221; <\/span><a href=\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss\"><span style=\"font-weight: 400;\">fda.gov<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">US Food and Drug Administration. Prescribing information for Wegovy, Ozempic, Zepbound and Mounjaro.<\/span><\/li>\n<\/ol>\n<h2 id=\"medical-disclaimer\"><span style=\"font-weight: 400;\">Medical disclaimer<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">This article is for informational and educational purposes only. It does not replace medical advice, diagnosis or treatment. It reflects publicly available clinical data and FDA labels as of October 2026. Clinical trial results are averages, and individual responses vary. Semaglutide and tirzepatide are prescription medications that require evaluation by a licensed healthcare provider. Do not start, stop or change any medication without talking to your doctor. Heally connects patients with independent licensed healthcare providers. Heally itself does not prescribe medications or provide medical advice. All prices are approximate and may change, so check costs with your pharmacy and insurance plan. Both medications carry an FDA boxed warning about the risk of thyroid C-cell tumors.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"Editorial note: Heally providers prescribe both semaglutide and tirzepatide, so we have a stake in this topic. We&hellip;\n","protected":false},"author":10,"featured_media":29840,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1838,1829],"tags":[2279,1860,2278,1831,1797,1793,1830,1832],"class_list":["post-29837","post","type-post","status-publish","format-standard","has-post-thumbnail","category-semaglutide-weight-loss","category-tirzepatide","tag-dosing","tag-glp-1","tag-medication-comparison","tag-mounjaro","tag-ozempic","tag-semaglutide","tag-tirzepatide","tag-zepbound"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally<\/title>\n<meta name=\"description\" content=\"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally\" \/>\n<meta property=\"og:description\" content=\"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you\" \/>\n<meta property=\"og:url\" content=\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\" \/>\n<meta property=\"og:site_name\" content=\"Heally\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/getheally.com\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-18T21:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-20T15:12:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ben Krasne MD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ben Krasne MD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#article\",\"isPartOf\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\"},\"author\":{\"name\":\"Ben Krasne MD\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211\"},\"headline\":\"Tirzepatide vs semaglutide: dosage, weight loss results and which is right for you (2026)\",\"datePublished\":\"2026-10-18T21:44:00+00:00\",\"dateModified\":\"2026-10-20T15:12:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\"},\"wordCount\":3477,\"publisher\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\"},\"thumbnailUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"keywords\":[\"Dosing\",\"glp-1\",\"Medication Comparison\",\"mounjaro\",\"Ozempic\",\"semaglutide\",\"tirzepatide\",\"zepbound\"],\"articleSection\":[\"Semaglutide\",\"Tirzepatide\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\",\"url\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\",\"name\":\"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally\",\"isPartOf\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\"},\"thumbnailUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"datePublished\":\"2026-10-18T21:44:00+00:00\",\"dateModified\":\"2026-10-20T15:12:44+00:00\",\"description\":\"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you\",\"breadcrumb\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage\",\"url\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"contentUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg\",\"width\":1000,\"height\":1000,\"caption\":\"what is the difference between tirzepatide and semaglutide dosing\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/getheally.com\/patients\/news\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide vs semaglutide: dosage, weight loss results and which is right for you (2026)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#website\",\"url\":\"https:\/\/getheally.com\/patients\/news\/\",\"name\":\"Heally\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/getheally.com\/patients\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#organization\",\"name\":\"Heally\",\"url\":\"https:\/\/getheally.com\/patients\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png\",\"contentUrl\":\"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png\",\"width\":152,\"height\":52,\"caption\":\"Heally\"},\"image\":{\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/getheally.com\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211\",\"name\":\"Ben Krasne MD\",\"pronouns\":\"Meet Dr. Benjamin Krasne, M.D., an anesthesiology and preventive medicine physician specializing in longevity and metabolic health at Heally\",\"description\":\"Dr. Benjamin Krasne is a board-certified Anesthesiologist with deep expertise in preventive medicine, metabolic health, and longevity optimization. He earned his medical degree from the University of Miami Leonard M. Miller School of Medicine in 2013 and completed his Anesthesiology residency at the University of Miami \/ Jackson Health System - one of the largest and most complex medical centers in the United States, providing broad exposure to high-acuity patient care and pharmacology. Beyond his anesthesiology training, Dr. Krasne has built specialized expertise in the root causes of metabolic and age-related disease. His approach draws on cardiovascular, hormonal, and metabolic science to proactively optimize health markers rather than waiting for disease to manifest. He holds active medical licenses across U.S. states, reflecting his commitment to expanding access to evidence-based preventive care through telehealth. At Heally, Dr. Krasne is the primary medical reviewer for the platform's largest content category - GLP-1 weight loss medications, including semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), oral Wegovy, longevity protocols, NAD+ therapy, sermorelin, methylene blue, acarbose, and peptide therapies. His pharmacological background and preventive medicine focus make him ideally suited to review clinical content on metabolic optimization.\",\"sameAs\":[\"https:\/\/www.parkwayrestorativedentistry.com\/dr-benjamin-krasne\"],\"url\":\"https:\/\/getheally.com\/patients\/news\/author\/ben-krasne-md\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally","description":"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","og_locale":"en_US","og_type":"article","og_title":"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally","og_description":"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you","og_url":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","og_site_name":"Heally","article_publisher":"https:\/\/getheally.com","article_published_time":"2026-10-18T21:44:00+00:00","article_modified_time":"2026-10-20T15:12:44+00:00","og_image":[{"width":1000,"height":1000,"url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","type":"image\/jpeg"}],"author":"Ben Krasne MD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ben Krasne MD","Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#article","isPartOf":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss"},"author":{"name":"Ben Krasne MD","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211"},"headline":"Tirzepatide vs semaglutide: dosage, weight loss results and which is right for you (2026)","datePublished":"2026-10-18T21:44:00+00:00","dateModified":"2026-10-20T15:12:44+00:00","mainEntityOfPage":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss"},"wordCount":3477,"publisher":{"@id":"https:\/\/getheally.com\/patients\/news\/#organization"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage"},"thumbnailUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","keywords":["Dosing","glp-1","Medication Comparison","mounjaro","Ozempic","semaglutide","tirzepatide","zepbound"],"articleSection":["Semaglutide","Tirzepatide"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","url":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss","name":"Tirzepatide and Semaglutide key differences, weight loss results (2026) - Heally","isPartOf":{"@id":"https:\/\/getheally.com\/patients\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage"},"thumbnailUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","datePublished":"2026-10-18T21:44:00+00:00","dateModified":"2026-10-20T15:12:44+00:00","description":"Tirzepatide vs semaglutide in 2026: compare weight loss, side effects, cost, and results from SURMOUNT-5. See which GLP-1 is right for you","breadcrumb":{"@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#primaryimage","url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","contentUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2024\/12\/tirzepatide_vs_semaglutide_dosage.jpg","width":1000,"height":1000,"caption":"what is the difference between tirzepatide and semaglutide dosing"},{"@type":"BreadcrumbList","@id":"https:\/\/getheally.com\/patients\/news\/tirzepatide-vs-semaglutide-dosage-for-weight-loss#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/getheally.com\/patients\/news"},{"@type":"ListItem","position":2,"name":"Tirzepatide vs semaglutide: dosage, weight loss results and which is right for you (2026)"}]},{"@type":"WebSite","@id":"https:\/\/getheally.com\/patients\/news\/#website","url":"https:\/\/getheally.com\/patients\/news\/","name":"Heally","description":"","publisher":{"@id":"https:\/\/getheally.com\/patients\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/getheally.com\/patients\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/getheally.com\/patients\/news\/#organization","name":"Heally","url":"https:\/\/getheally.com\/patients\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/","url":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png","contentUrl":"https:\/\/getheally.com\/patients\/news\/wp-content\/uploads\/2019\/05\/heallybl.png","width":152,"height":52,"caption":"Heally"},"image":{"@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/getheally.com"]},{"@type":"Person","@id":"https:\/\/getheally.com\/patients\/news\/#\/schema\/person\/133ab039fcce2b4f2ef87ae214ab9211","name":"Ben Krasne MD","pronouns":"Meet Dr. Benjamin Krasne, M.D., an anesthesiology and preventive medicine physician specializing in longevity and metabolic health at Heally","description":"Dr. Benjamin Krasne is a board-certified Anesthesiologist with deep expertise in preventive medicine, metabolic health, and longevity optimization. He earned his medical degree from the University of Miami Leonard M. Miller School of Medicine in 2013 and completed his Anesthesiology residency at the University of Miami \/ Jackson Health System - one of the largest and most complex medical centers in the United States, providing broad exposure to high-acuity patient care and pharmacology. Beyond his anesthesiology training, Dr. Krasne has built specialized expertise in the root causes of metabolic and age-related disease. His approach draws on cardiovascular, hormonal, and metabolic science to proactively optimize health markers rather than waiting for disease to manifest. He holds active medical licenses across U.S. states, reflecting his commitment to expanding access to evidence-based preventive care through telehealth. At Heally, Dr. Krasne is the primary medical reviewer for the platform's largest content category - GLP-1 weight loss medications, including semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), oral Wegovy, longevity protocols, NAD+ therapy, sermorelin, methylene blue, acarbose, and peptide therapies. His pharmacological background and preventive medicine focus make him ideally suited to review clinical content on metabolic optimization.","sameAs":["https:\/\/www.parkwayrestorativedentistry.com\/dr-benjamin-krasne"],"url":"https:\/\/getheally.com\/patients\/news\/author\/ben-krasne-md"}]}},"_links":{"self":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/comments?post=29837"}],"version-history":[{"count":23,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29837\/revisions"}],"predecessor-version":[{"id":37977,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/posts\/29837\/revisions\/37977"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/media\/29840"}],"wp:attachment":[{"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/media?parent=29837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/categories?post=29837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/getheally.com\/patients\/news\/wp-json\/wp\/v2\/tags?post=29837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}